On April 11, 2025, GSK plc reported that two executives, David Redfern and Victoria Whyte, acquired ordinary shares following dividend reinvestments from dividends paid on April 10, 2025. Redfern purchased 25 shares at £12.73 each and Whyte purchased 22 shares at the same price.